eLife (Jun 2020)
Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19
- Nick K Jones,
- Lucy Rivett,
- Dominic Sparkes,
- Sally Forrest,
- Sushmita Sridhar,
- Jamie Young,
- Joana Pereira-Dias,
- Claire Cormie,
- Harmeet Gill,
- Nicola Reynolds,
- Michelle Wantoch,
- Matthew Routledge,
- Ben Warne,
- Jack Levy,
- William David Córdova Jiménez,
- Fathima Nisha Begum Samad,
- Chris McNicholas,
- Mark Ferris,
- Jane Gray,
- Michael Gill,
- The CITIID-NIHR COVID-19 BioResource Collaboration,
- Martin D Curran,
- Stewart Fuller,
- Afzal Chaudhry,
- Ashley Shaw,
- John R Bradley,
- Gregory J Hannon,
- Ian G Goodfellow,
- Gordon Dougan,
- Kenneth GC Smith,
- Paul J Lehner,
- Giles Wright,
- Nicholas J Matheson,
- Stephen Baker,
- Michael P Weekes
Affiliations
- Nick K Jones
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Lucy Rivett
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Dominic Sparkes
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Sally Forrest
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Sushmita Sridhar
- ORCiD
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom; Wellcome Sanger Institute, Hinxton, United Kingdom
- Jamie Young
- Academic Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom
- Joana Pereira-Dias
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Claire Cormie
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Harmeet Gill
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Nicola Reynolds
- Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Michelle Wantoch
- Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; Department of Haematology, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom
- Matthew Routledge
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Ben Warne
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Jack Levy
- Institute for Manufacturing, Department of Engineering, University of Cambridge, Cambridge, United Kingdom
- William David Córdova Jiménez
- Institute for Manufacturing, Department of Engineering, University of Cambridge, Cambridge, United Kingdom
- Fathima Nisha Begum Samad
- Institute for Manufacturing, Department of Engineering, University of Cambridge, Cambridge, United Kingdom
- Chris McNicholas
- Improvement and Transformation Team, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Mark Ferris
- Occupational Health and Wellbeing, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Jane Gray
- Cancer Research United Kingdom Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Michael Gill
- Cancer Research United Kingdom Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- The CITIID-NIHR COVID-19 BioResource Collaboration
- Martin D Curran
- Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Stewart Fuller
- National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom
- Afzal Chaudhry
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Ashley Shaw
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- John R Bradley
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; National Institutes for Health Research Cambridge, Clinical Research Facility, Cambridge, United Kingdom
- Gregory J Hannon
- ORCiD
- Cancer Research United Kingdom Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Ian G Goodfellow
- ORCiD
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- Gordon Dougan
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Kenneth GC Smith
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Paul J Lehner
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Giles Wright
- Occupational Health and Wellbeing, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Nicholas J Matheson
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant, Cambridge, United Kingdom
- Stephen Baker
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Michael P Weekes
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.59391
- Journal volume & issue
-
Vol. 9
Abstract
Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs) from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020. About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with COVID-19 during the ongoing UK ‘lockdown’. These data demonstrate how infection prevention and control measures including staff testing may help prevent hospitals from becoming independent ‘hubs’ of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions, organizations in other sectors may be able to resume on-site work safely.
Keywords
